Announcements
- Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
- Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
- Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
- Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
- Editas Medicine Announces First Quarter 2024 Results and Business Updates
- Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
- Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.02 |
---|---|
High | 4.02 |
Low | 4.02 |
Bid | 4.17 |
Offer | 4.44 |
Previous close | 4.08 |
Average volume | 1.73k |
---|---|
Shares outstanding | 82.24m |
Free float | 81.95m |
P/E (TTM) | -- |
Market cap | 373.36m USD |
EPS (TTM) | -2.10 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 07:03 BST.
More ▼